In this latest episode of ASTCT Talks, Christina Cho, MD, interviews Lori Muffly, MD, MS. During the conversation, Dr. Muffly emphasizes the need for more randomized data in ALL treatment and addresses the unique challenges of treating young adults, including fertility preservation. Dr. Muffly also emphasizes the significance of measurable residual disease (MRD) monitoring using the clonoSEQ® Assay, offering valuable insights into leukemia care.
About Lori Muffly, MD, MS
Lori Muffly, MD, MS, an Associate Professor of Medicine at Stanford University, specializes in adult acute leukemia research, clinical trials, and hematopoietic cell transplantation. Her work focuses on improving cancer care access and reducing disparities in young adults with acute lymphoblastic leukemia. Dr. Muffly leads multiple health outcomes studies and clinical trials, including research on measurable residual disease, CAR T-cell therapies, and real-world outcomes for adult acute lymphoblastic leukemia patients. She has a history of successful collaboration with fellow researchers and is a sought-after national speaker on adolescent and young adult leukemia and cancer care access.
About Christina Cho, MD
Christina Cho, MD is a hematologist/oncologist specializing in adult stem cell transplantation and cellular therapy at Hackensack University Medical Center’s John Theurer Cancer Center. Dr. Cho conducts clinical research on stem cell transplantation, including therapies for leukemia and sickle cell disease. She is an active member of the American Society of Hematology and the American Society for Transplantation and Cellular Therapy and currently serves as editor for ASTCT Nucleus.
Tags: MRD, MRD testing, leukemia, ALL, MRD negativity